AU2014259956A1 - Methods of treating cancer - Google Patents

Methods of treating cancer Download PDF

Info

Publication number
AU2014259956A1
AU2014259956A1 AU2014259956A AU2014259956A AU2014259956A1 AU 2014259956 A1 AU2014259956 A1 AU 2014259956A1 AU 2014259956 A AU2014259956 A AU 2014259956A AU 2014259956 A AU2014259956 A AU 2014259956A AU 2014259956 A1 AU2014259956 A1 AU 2014259956A1
Authority
AU
Australia
Prior art keywords
fgfr1
cancer
ecd
fgfr1 ecd
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014259956A
Other languages
English (en)
Inventor
Maureen R. Bleam
Maurice P. DEYOUNG
Geraldine FERRON-BRADY
Julie Hambleton
Rakesh Kumar
Lone Ottesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Five Prime Therapeutics Inc
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd, Five Prime Therapeutics Inc filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of AU2014259956A1 publication Critical patent/AU2014259956A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014259956A 2013-05-01 2014-04-30 Methods of treating cancer Abandoned AU2014259956A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361818220P 2013-05-01 2013-05-01
US61/818,220 2013-05-01
US201361831029P 2013-06-04 2013-06-04
US61/831,029 2013-06-04
PCT/US2014/036140 WO2014179448A2 (en) 2013-05-01 2014-04-30 Methods of treating cancer

Publications (1)

Publication Number Publication Date
AU2014259956A1 true AU2014259956A1 (en) 2015-11-12

Family

ID=50928263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014259956A Abandoned AU2014259956A1 (en) 2013-05-01 2014-04-30 Methods of treating cancer

Country Status (13)

Country Link
US (2) US20160067307A1 (enExample)
EP (1) EP2991669A2 (enExample)
JP (1) JP2016526016A (enExample)
KR (1) KR20160003141A (enExample)
CN (1) CN105188732A (enExample)
AU (1) AU2014259956A1 (enExample)
BR (1) BR112015027607A8 (enExample)
CA (1) CA2908391A1 (enExample)
HK (1) HK1213817A1 (enExample)
MX (1) MX2015015115A (enExample)
RU (1) RU2015150233A (enExample)
SG (1) SG11201508878WA (enExample)
WO (1) WO2014179448A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
PE20160190A1 (es) 2013-08-01 2016-04-28 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
KR20180028524A (ko) * 2015-07-24 2018-03-16 데비오팜 인터네셔날 에스 에이 Fgfr 발현 및 fgfr 억제제에 대한 민감성
BR112018010410A8 (pt) * 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
PL238516B1 (pl) 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
AU2018215794A1 (en) * 2017-02-06 2019-07-25 Fusion Pharmaceuticals Inc. Methods, compositions, and kits for treatment of cancer
WO2018195273A1 (en) * 2017-04-19 2018-10-25 The Corporation Of Mercer University Sam-1 protein, composition and methods of use
CN110621336B (zh) 2017-05-16 2024-05-14 戊瑞治疗有限公司 癌症治疗中抗fgfr2抗体与化学治疗剂的组合

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US20090105329A1 (en) * 2005-11-04 2009-04-23 Judy Chiao Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8481038B2 (en) * 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
NZ703786A (en) * 2010-11-15 2016-08-26 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CN107823630A (zh) * 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法

Also Published As

Publication number Publication date
US20180280470A1 (en) 2018-10-04
WO2014179448A3 (en) 2014-12-24
RU2015150233A (ru) 2017-06-02
BR112015027607A2 (pt) 2017-12-05
KR20160003141A (ko) 2016-01-08
WO2014179448A2 (en) 2014-11-06
CA2908391A1 (en) 2014-11-06
HK1213817A1 (zh) 2016-07-15
MX2015015115A (es) 2016-06-07
BR112015027607A8 (pt) 2018-01-23
EP2991669A2 (en) 2016-03-09
SG11201508878WA (en) 2015-11-27
US20160067307A1 (en) 2016-03-10
CN105188732A (zh) 2015-12-23
JP2016526016A (ja) 2016-09-01

Similar Documents

Publication Publication Date Title
US10537611B2 (en) Methods of treating lung cancer
US20180280470A1 (en) Methods of treating cancer
JP6095367B2 (ja) 癌治療のための診断方法および組成物
ES2541925T3 (es) Métodos y composiciones para el uso diagnóstico en pacientes de cáncer
JP2011527582A (ja) 腫瘍治療のための診断のための方法および組成物
US9775881B2 (en) Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period